Table of Contents
ISRN Oncology
Volume 2011 (2011), Article ID 617593, 13 pages
http://dx.doi.org/10.5402/2011/617593
Review Article

Review of Breast Conservation Therapy: Then and Now

1Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Received 1 April 2011; Accepted 11 May 2011

Academic Editor: Y. Yamamoto

Copyright © 2011 Susan Hoover et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. U. Veronesi, B. Salvadori, A. Luini et al., “Breast conservation is a safe method in patients with small cancer of the breast. Long term results of three randomized trials on 1973 patients,” European Journal of Cancer—Part A, vol. 31, no. 10, pp. 1574–1579, 1995. View at Publisher · View at Google Scholar
  2. B. Fisher, C. Redmond, R. Poisson et al., “Eight year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer,” The New England Journal of Medicine, vol. 320, no. 13, pp. 822–828, 1989. View at Google Scholar
  3. D. Sarazin, M. G. Lê, R. Arriagada et al., “Ten year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer,” Radiotherapy & Oncology, vol. 14, pp. 177–184, 1989. View at Google Scholar
  4. J. A. Van Dongen, H. Bartelink, I. S. Fentiman et al., “Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancer,” European Journal of Cancer—Part A, vol. 28, no. 4-5, pp. 801–805, 1992. View at Google Scholar
  5. A. S. Lichter, M. E. Lippman, D. N. Danforth et al., “Mastectomy versus breast conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute,” Journal of Clinical Oncology, vol. 10, no. 6, pp. 976–983, 1992. View at Google Scholar
  6. W. Halstead, “The results of operations for cure of cancer of the breast performed at Johns Hopkins Hospital,” Bulletin of the Johns Hopkins Hospital, vol. 4, p. 497, 1894. View at Google Scholar
  7. W. S. Halstead, “The results of radical operations for the cure of carcinoma of the breast,” Annals of Surgery, vol. 66, p. 1, 1907. View at Google Scholar
  8. G. Keynes, “Breast cancer: a case for conservation,” The British Medical Journal, vol. 282, no. 6273, p. 1392, 1981. View at Google Scholar
  9. G. N. Robinson, J. A. Van Heerden, and W. S. Payne, “The primary surgical treatment of carcinoma of the breast: a changing trend toward modified radical mastectomy,” Mayo Clinic Proceedings, vol. 51, no. 7, pp. 433–442, 1976. View at Google Scholar
  10. R. R. Baker, A. C. W. Montague, and J. N. Childs, “A comparison of modified radical mastectomy to radical mastectomy in the treatment of operable breast cancer,” Annals of Surgery, vol. 189, no. 5, pp. 553–559, 1979. View at Google Scholar
  11. L. Turner, R. Swindell, and W. G. T. Bell, “Radical versus modified radical mastectomy for breast cancer,” Annals of the Royal College of Surgeons of England, vol. 63, no. 4, pp. 239–243, 1981. View at Google Scholar
  12. W. A. Maddox, J. T. Carpenter, and H. L. Laws, “A randomized prospective trial of radical (Halstead) mastectomy versus modified radical mastecomy in 311 breast cancer patients,” Annals of Surgery, vol. 198, no. 2, pp. 207–212, 1983. View at Google Scholar
  13. T. Ashikaga, D. N. Krag, S. R. Land et al., “Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection,” Journal of Surgical Oncology, vol. 102, no. 2, pp. 111–118, 2010. View at Publisher · View at Google Scholar · View at PubMed
  14. D. Lazovich, C. C. Solomon, D. B. Thomas, R. E. Moe, and E. White, “Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma,” Cancer, vol. 86, no. 4, pp. 628–637, 1999. View at Publisher · View at Google Scholar
  15. M. C. Lee, K. Rogers, K. Griffith et al., “Determinants of breast conservation rates: reasons for mastectomy at a comprehensive cancer center,” Breast Journal, vol. 15, no. 1, pp. 34–40, 2009. View at Publisher · View at Google Scholar · View at PubMed
  16. S. J. Katz, P. M. Lantz, N. K. Janz et al., “Patient involvement in surgery treatment decisions for breast cancer,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5526–5533, 2005. View at Publisher · View at Google Scholar · View at PubMed
  17. P. M. Lantz, N. K. Janz, A. Fagerlin et al., “Satisfaction with surgery outcomes and the decision process in a population-based sample of women with breast cancer,” Health Services Research, vol. 40, no. 3, pp. 745–767, 2005. View at Publisher · View at Google Scholar · View at PubMed
  18. S. J. Katz, P. M. Lantz, N. K. Janz et al., “Surgeon perspectives about local therapy for breast carcinoma,” Cancer, vol. 104, no. 9, pp. 1854–1861, 2005. View at Publisher · View at Google Scholar · View at PubMed
  19. S. J. Katz, P. M. Lantz, N. K. Janz et al., “Patterns and correlates of local therapy for women with ductal carcinoma in situ,” Journal of Clinical Oncology, vol. 23, no. 13, pp. 3001–3007, 2005. View at Publisher · View at Google Scholar · View at PubMed
  20. R. S. J. Foster, M. E. Farwell, and M. C. Costanza, “Breast-conserving surgery for breast cancer: patterns of care in a geographic region and estimation of potential applicability,” Annals of Surgical Oncology, vol. 2, no. 3, pp. 275–280, 1995. View at Publisher · View at Google Scholar
  21. F. Meric, “Breast conservation in breast cancer: surgical and adjuvant considerations,” Current Opinion in Obstetrics and Gynecology, vol. 16, no. 1, pp. 31–36, 2004. View at Publisher · View at Google Scholar
  22. N. L. Keating, J. C. Weeks, C. Borbas, and E. Guadagnoli, “Treatment of early stage breast cancer: do surgeons and patients agree regarding whether treatment alternatives were discussed?” Breast Cancer Research and Treatment, vol. 79, no. 2, pp. 225–231, 2003. View at Publisher · View at Google Scholar
  23. M. Morrow, J. White, J. Moughan et al., “Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma,” Journal of Clinical Oncology, vol. 19, no. 8, pp. 2254–2262, 2001. View at Google Scholar
  24. M. Morrow, C. Bucci, and A. Rademaker, “Medical contraindications are not a major factor in underutilization of breast conserving therapy,” Journal of the American College of Surgeons, vol. 186, no. 3, pp. 269–274, 1998. View at Publisher · View at Google Scholar
  25. S. A. Savin, S. M. Love, and N. L. Sadowsky, “Reconstruction of the radiated partial mastectomy defect with autogenous tissues,” Plastic and Reconstructive Surgery, vol. 90, pp. 854–865, 1992. View at Google Scholar
  26. H. T. Wang, C. M. Barone, M. B. Steigelman et al., “Aesthetic outcomes in breast conservation therapy,” Aesthetic Surgery Journal, vol. 28, no. 2, pp. 165–170, 2008. View at Publisher · View at Google Scholar · View at PubMed
  27. M. Hanjoon, T. M. Styblo, G. W. Carlson, and A. Losken, “The use of oncoplastic reduction techniques to reconstruct partial mastectomy defects in women with ductal carcinoma in situ,” Breast Journal, vol. 16, no. 2, pp. 141–146, 2010. View at Publisher · View at Google Scholar · View at PubMed
  28. M. J. Silverstein, “How I do it: oncoplastic breast-conservation surgery,” Annals of Surgical Oncology, vol. 17, no. 3, pp. S242–S244, 2010. View at Publisher · View at Google Scholar · View at PubMed
  29. T. J. Meretoja, C. Svarvar, and T. A. Jahkola, “Outcome of oncoplastic breast surgery in 90 prospective patients,” The American Journal of Surgery, vol. 200, no. 2, pp. 224–228, 2010. View at Publisher · View at Google Scholar · View at PubMed
  30. N. Patani and R. Carpenter, “Oncological and aesthetic considerations of conservational surgery for multifocal/multicentric breast cancer,” Breast Journal, vol. 16, no. 3, pp. 222–232, 2010. View at Publisher · View at Google Scholar · View at PubMed
  31. J. Bong, J. Parker, R. Clapper, and W. Dooley, “Clinical series of oncoplastic mastopexy to optimize cosmesis of large-volume resections for breast conservation,” Annals of Surgical Oncology, vol. 17, pp. 3247–3251, 2010. View at Publisher · View at Google Scholar · View at PubMed
  32. S. Chia, S. M. Swain, D. R. Byrd, and D. A. Mankoff, “Locally advanced and inflammatory breast cancer,” Journal of Clinical Oncology, vol. 26, no. 5, pp. 786–790, 2008. View at Publisher · View at Google Scholar · View at PubMed
  33. J. G. H. van Nes, H. Putter, J. P. Julien et al., “Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902,” Breast Cancer Research and Treatment, vol. 115, no. 1, pp. 101–113, 2009. View at Publisher · View at Google Scholar · View at PubMed
  34. P. Rastogi, S. J. Anderson, H. D. Bear et al., “Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27,” Journal of Clinical Oncology, vol. 26, no. 5, pp. 778–785, 2008. View at Publisher · View at Google Scholar · View at PubMed
  35. D. Mauri, N. Pavlidis, and J. P. A. Ioannidis, “Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis,” Journal of the National Cancer Institute, vol. 97, no. 3, pp. 188–194, 2005. View at Publisher · View at Google Scholar · View at PubMed
  36. J. S. Mieog, J. A. van der Hage, and C. J. van de Velde, “Preoperative chemotherapy for women with operable breast cancer,” Cochrane Database of Systematic Reviews, no. 2, p. CD005002, 2007. View at Google Scholar
  37. A. M. Chen, F. Meric-Bernstam, K. K. Hunt et al., “Breast conservation after neoadjuvant chemotherapy: the M.D. Anderson cancer center experience,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2303–2312, 2004. View at Publisher · View at Google Scholar · View at PubMed
  38. A. M. Chen, F. Meric-Bernstam, K. K. Hunt et al., “Breast conservation after neoadjuvant chemotherapy,” Cancer, vol. 103, no. 4, pp. 689–695, 2005. View at Publisher · View at Google Scholar · View at PubMed
  39. W. F. Symmans, F. Peintinger, C. Hatzis et al., “Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy,” Journal of Clinical Oncology, vol. 25, no. 28, pp. 4414–4422, 2007. View at Publisher · View at Google Scholar · View at PubMed
  40. National Comprehensive Cancer Network, “NCCN breast guidelines v2.2011,” 2011, http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. View at Google Scholar
  41. G. von Minckwitz, G. Raab, A. Caputo et al., “Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group,” Journal of Clinical Oncology, vol. 23, no. 12, pp. 2676–2685, 2005. View at Publisher · View at Google Scholar · View at PubMed
  42. A. U. Buzdar, V. Valero, N. K. Ibrahim et al., “Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen,” Clinical Cancer Research, vol. 13, no. 1, pp. 228–233, 2007. View at Publisher · View at Google Scholar · View at PubMed
  43. L. Gianni, W. Eiermann, V. Semiglazov et al., “Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort,” The Lancet, vol. 375, no. 9712, pp. 377–384, 2010. View at Publisher · View at Google Scholar
  44. I. C. Smith, S. D. Heys, A. W. Hutcheon et al., “Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel,” Journal of Clinical Oncology, vol. 20, no. 6, pp. 1456–1466, 2002. View at Publisher · View at Google Scholar
  45. G. von Minckwitz, S. Kümmel, P. Vogel et al., “Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial,” Journal of the National Cancer Institute, vol. 100, no. 8, pp. 542–551, 2008. View at Publisher · View at Google Scholar · View at PubMed
  46. A. Katz, E. D. Saad, P. Porter, and L. Pusztai, “Primary systemic chemotherapy of invasive lobular carcinoma of the breast,” The Lancet Oncology, vol. 8, no. 1, pp. 55–62, 2007. View at Publisher · View at Google Scholar · View at PubMed
  47. M. Cristofanilli, A. Gonzalez-Angulo, N. Sneige et al., “Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes,” Journal of Clinical Oncology, vol. 23, no. 1, pp. 41–48, 2005. View at Publisher · View at Google Scholar · View at PubMed
  48. A. Purushotham, S. Pinder, M. Cariati, M. Harries, and A. Goldhirsch, “Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast?” Journal of Clinical Oncology, vol. 28, no. 22, pp. 3552–3554, 2010. View at Publisher · View at Google Scholar · View at PubMed
  49. L. Gianni, J. Baselga, W. Eiermann et al., “Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy,” Clinical Cancer Research, vol. 11, no. 24, part 1, pp. 8715–8721, 2005. View at Publisher · View at Google Scholar · View at PubMed
  50. V. Guarneri, K. Broglio, S. W. Kau et al., “Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors,” Journal of Clinical Oncology, vol. 24, no. 7, pp. 1037–1044, 2006. View at Publisher · View at Google Scholar · View at PubMed
  51. T. Sorlie, R. Tibshirani, J. Parker et al., “Repeated observation of breast tumor subtypes in independent gene expression data sets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8418–8423, 2003. View at Publisher · View at Google Scholar · View at PubMed
  52. A. S. Caudle, A. M. Gonzalez-Angulo, K. K. Hunt et al., “Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer,” Journal of Clinical Oncology, vol. 28, no. 11, pp. 1821–1828, 2010. View at Publisher · View at Google Scholar · View at PubMed
  53. M. J. Ellis and C. Ma, “Letrozole in the neoadjuvant setting: the P024 trial,” Breast Cancer Research and Treatment, vol. 105, supplement 1, pp. 33–43, 2007. View at Google Scholar
  54. I. E. Smith, M. Dowsett, S. R. Ebbs et al., “Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 5108–5116, 2005. View at Publisher · View at Google Scholar · View at PubMed
  55. L. Cataliotti, A. U. Buzdar, S. Noguchi et al., “Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative “Arimidex” compared to tamoxifen (PROACT) trial,” Cancer, vol. 106, no. 10, pp. 2095–2103, 2006. View at Publisher · View at Google Scholar · View at PubMed
  56. V. F. Semiglazov, V. V. Semiglazov, G. A. Dashyan et al., “Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer,” Cancer, vol. 110, no. 2, pp. 244–254, 2007. View at Publisher · View at Google Scholar · View at PubMed
  57. Y. H. Chia, M. J. Ellis, and C. X. Ma, “Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool,” The British Journal of Cancer, vol. 103, no. 6, pp. 759–764, 2010. View at Publisher · View at Google Scholar · View at PubMed
  58. M. J. Ellis, Y. Tao, J. Luo et al., “Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics,” Journal of the National Cancer Institute, vol. 100, no. 19, pp. 1380–1388, 2008. View at Publisher · View at Google Scholar · View at PubMed
  59. J. Huober, G. von Minckwitz, C. Denkert et al., “Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study,” Breast Cancer Research and Treatment, vol. 124, no. 1, pp. 133–140, 2010. View at Publisher · View at Google Scholar · View at PubMed
  60. T. A. Buchholz, “Radiation therapy for early-stage breast cancer after breast-conserving surgery,” The New England Journal of Medicine, vol. 360, no. 1, pp. 6–70, 2009. View at Publisher · View at Google Scholar · View at PubMed
  61. U. Veronesi, E. Marubini, L. Mariani et al., “Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial,” Annals of Oncology, vol. 12, no. 7, pp. 997–1003, 2001. View at Publisher · View at Google Scholar
  62. R. M. Clark, P. B. McCulloch, M. N. Levine et al., “Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer,” Journal of the National Cancer Institute, vol. 84, no. 9, pp. 683–689, 1992. View at Google Scholar
  63. L. Holmberg, “Sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial,” Journal of the National Cancer Institute, vol. 82, no. 4, pp. 277–282, 1990. View at Google Scholar
  64. T. J. Whelan, J. P. Pignol, M. N. Levine et al., “Long-term results of hypofractionated radiation therapy for breast cancer,” The New England Journal of Medicine, vol. 362, no. 6, pp. 513–520, 2010. View at Publisher · View at Google Scholar · View at PubMed
  65. A. Harsolia, L. Kestin, I. Grills et al., “Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 68, no. 5, pp. 1375–1380, 2007. View at Publisher · View at Google Scholar · View at PubMed
  66. Y. O. Borghero, M. Salehpour, M. D. McNeese et al., “Multileaf field-in-field forward-planned intensity-modulated dose compensation for whole-breast irradiation is associated with reduced contralateral breast dose: a phantom model comparison,” Radiotherapy and Oncology, vol. 82, no. 3, pp. 324–328, 2007. View at Publisher · View at Google Scholar · View at PubMed
  67. M. Clarke, O. Abe, R. Abe et al., “Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials,” Lancet, vol. 366, no. 9503, pp. 2087–2106, 2005. View at Publisher · View at Google Scholar · View at PubMed
  68. K. E. Sixel, M. C. Aznar, and Y. C. Ung, “Deep inspiration breath hold to reduce irradiated heart volume in breast cancer patients,” International Journal of Radiation Oncology Biology Physics, vol. 49, no. 1, pp. 199–204, 2001. View at Publisher · View at Google Scholar
  69. F. Vicini, P. Beitsch, C. Quiet et al., “Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons mammosite breast brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation,” International Journal of Radiation Oncology, Biology, Physics, vol. 79, no. 3, pp. 808–817, 2010. View at Publisher · View at Google Scholar · View at PubMed
  70. F. Vicini, K. Winter, J. Wong et al., “Initial efficacy results of RTOG 0319: three-dimensional conformal radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/ II breast carcinoma,” International Journal of Radiation Oncology, Biology, Physics, vol. 77, no. 4, pp. 1120–1127, 2010. View at Publisher · View at Google Scholar · View at PubMed
  71. F. A. Vicini, J. V. Antonucci, M. Wallace et al., “Long-term efficacy and patterns of failure after accelerated partial breast irradiation: a molecular assay-based clonality evaluation,” International Journal of Radiation Oncology, Biology, Physics, vol. 68, no. 2, pp. 341–346, 2007. View at Publisher · View at Google Scholar · View at PubMed
  72. D. W. Arthur, K. Winter, R. R. Kuske et al., “A Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17,” International Journal of Radiation Oncology, Biology, Physics, vol. 72, no. 2, pp. 467–473, 2008. View at Publisher · View at Google Scholar · View at PubMed
  73. A. Dickler, S. Chopra, C. Nguyen, and K. Dowlat, “Treatment volume and dose optimization of mammosite breast brachytherapy applicator,” International Journal of Radiation Oncology, Biology, Physics, vol. 59, no. 2, pp. 469–474, 2004. View at Google Scholar
  74. G. K. Edmundson, F. A. Vicini, P. Y. Chen, C. Mitchell, and A. A. Martinez, “Dosimetric characteristics of the MammoSite RTS, a new breast brachytherapy applicator,” International Journal of Radiation Oncology, Biology, Physics, vol. 52, no. 4, pp. 1132–1139, 2002. View at Publisher · View at Google Scholar
  75. NSABP Protocol B-39/RTOG Protocol 0413.
  76. S. F. Shaitelman, L. H. Kim, D. A. Mus et al., “Continuous arc rotation of the couch therapy for the delivery of accelerated partial breast irradiation: a treatment planning analysis,” International Journal of Radiation Oncology, Biology, Physics, vol. 80, no. 3, pp. 771–778, 2010. View at Publisher · View at Google Scholar · View at PubMed
  77. S. Sioshansi, M. J. Rivard, J. R. Hiatt, A. A. Hurley, Y. Lee, and D. E. Wazer, “Dose modeling of noninvasive image-guided breast brachytherapy in comparison to electron beam boost and three-dimensional conformal accelerated partial breast irradiation,” International Journal of Radiation Oncology, Biology, Physics, vol. 80, no. 2, pp. 410–416, 2010. View at Publisher · View at Google Scholar · View at PubMed
  78. X. Wang, R. A. Amos, X. Zhang et al., “External-beam accelerated partial breast irradiation using multiple proton beam configurations,” International Journal of Radiation Oncology, Biology, Physics, vol. 80, no. 5, pp. 1464–1472, 2010. View at Publisher · View at Google Scholar · View at PubMed